{"id":"belimumab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Bronchitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL1789843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Belimumab binds to soluble BLyS (also known as BAFF), a cytokine essential for B cell survival and maturation. By neutralizing BLyS, the drug decreases B cell activation, proliferation, and differentiation into plasma cells, thereby reducing pathogenic autoantibodies and immune-mediated inflammation characteristic of systemic lupus erythematosus and other B cell-driven autoimmune conditions.","oneSentence":"Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in autoimmune diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:55.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Lupus nephritis"}]},"trialDetails":[{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT06381453","phase":"PHASE2","title":"Belimumab in Autoimmune Hepatitis","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-12-11","conditions":"Autoimmune Hepatitis","enrollment":48},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT03370263","phase":"","title":"BENLYSTA® Special Drug Use Investigation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-01-15","conditions":"Systemic Lupus Erythematosus","enrollment":1514},{"nctId":"NCT05917288","phase":"PHASE1","title":"A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-07","conditions":"Systemic Lupus Erythematosus","enrollment":16},{"nctId":"NCT04179032","phase":"PHASE2","title":"Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-11-28","conditions":"Systemic Lupus Erythematosus","enrollment":25},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT04611971","phase":"PHASE1","title":"A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-27","conditions":"Healthy","enrollment":13},{"nctId":"NCT03747159","phase":"PHASE3","title":"Synergetic B-cell Immunomodulation in SLE - 2nd Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-10-01","conditions":"Lupus Erythematosus, Systemic","enrollment":70},{"nctId":"NCT03543839","phase":"PHASE4","title":"Trial of Belimumab in Early Lupus","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":"Lupus Erythematosus, Systemic, Lupus Erythematosus","enrollment":30},{"nctId":"NCT04447053","phase":"PHASE4","title":"Sequential Belimumab and T-cell Based Therapy in SLE","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2021-11-08","conditions":"Systemic Lupus Erythematosus","enrollment":80},{"nctId":"NCT05863936","phase":"PHASE3","title":"Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis","status":"UNKNOWN","sponsor":"Nanjing University School of Medicine","startDate":"2023-04-01","conditions":"Lupus Nephritis, Remission, Safety Issues","enrollment":15},{"nctId":"NCT03967925","phase":"PHASE2","title":"Rituximab and Belimumab Combination Therapy in PR3 Vasculitis","status":"UNKNOWN","sponsor":"Rachel Jones","startDate":"2019-02-01","conditions":"ANCA Associated Vasculitis, Granulomatosis With Polyangiitis","enrollment":31},{"nctId":"NCT02631538","phase":"PHASE2","title":"Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-17","conditions":"Sjogren's Syndrome","enrollment":86},{"nctId":"NCT04136145","phase":"PHASE1","title":"Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-28","conditions":"Systemic Lupus Erythematosus","enrollment":36},{"nctId":"NCT02880852","phase":"PHASE1","title":"Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-23","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT03154385","phase":"NA","title":"Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-03-13","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT01381536","phase":"PHASE1","title":"Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-20","conditions":"Systemic Lupus Erythematosus","enrollment":12},{"nctId":"NCT01894360","phase":"PHASE1","title":"A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-14","conditions":"Systemic Lupus Erythematosus","enrollment":81},{"nctId":"NCT01762852","phase":"PHASE2","title":"Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Glomerulonephritis, Membranous","enrollment":""},{"nctId":"NCT01583530","phase":"PHASE1","title":"Study of Belimumab Administered Subcutaneously to Healthy Subjects","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2011-02","conditions":"Healthy","enrollment":118},{"nctId":"NCT00732940","phase":"PHASE2","title":"Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Human Genome Sciences Inc.","startDate":"2008-10","conditions":"Systemic Lupus Erythematosus","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Beliumab induction therapy","Benlysta subcutaneous injection of 200mg"],"phase":"phase_3","status":"active","brandName":"Belimumab Injection","genericName":"Belimumab Injection","companyName":"Nanjing University School of Medicine","companyId":"nanjing-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in autoimmune diseases. Used for Systemic lupus erythematosus (SLE), Lupus nephritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}